FIGURE LEGENDS
Figure 1
The accumulative number of patients with rapid-rate non-sustained ventricular tachycardia (RR-NSVT) of different groups:
A: Whole study group: 50.0% (68/136) of patients experienced at least 1 RR-NSVT, 33.8% (46/136) of patients experienced 2 episodes of RR-NSVT, 25.7% (35/136) of patients experienced 3 episodes of RR-NSVT, and 25.0% (34/136) of patients experienced more than 3 episodes of RR-NSVT. There was a significant difference between the first and second accumulative incidence (p=0.010).
B: Primary prevention group: 48.7% (37/76) of patients experienced at least 1 RR-NSVT, 30.2% (23/76) of patients experienced 2 episodes of RR-NSVT, 19.7% (15/76) of patients experienced 3 episodes of RR-NSVT, and 18.4% (14/76) of patients experienced more than 3 episodes of RR-NSVT. There was a significant difference between the first and second accumulative incidence (p=0.033).
C: Secondary prevention group: 51.7% (31/60) of patients experienced at least 1 RR-NSVT, 38.3% (23/60) of patients experienced 2 episodes of RR-NSVT, and 33.3% (20/60) of patients experienced more than 2 episodes of RR-NSVT. There was no significant difference between any accumulative incidence.
Figure 2
A Kaplan-Meier curve of clinical outcomes
A: A Kaplan-Meier curve on the occurrence of VTAs. There was a significant difference between the RR-NSVT (-) and RR-NSVT (+) groups (log-rank p<0.001).
B: Patients of primary prevention. There was a significant difference between the RR-NSVT (-) and RR-NSVT (+) groups (log-rank p<0.001).
C: Patients of secondary prevention. There was a significant difference between the RR-NSVT (-) and RR-NSVT (+) groups (log-rank p=0.002).
Figure 3
A: A Kaplan-Meier curve on the admission for heart failure. There was no significant difference between the RR-NSVT (-) and RR-NSVT (+) groups (log-rank p=0.494)
B: A Kaplan-Meier curve on cardiovascular mortality. There was no significant difference between the RR-NSVT (-) and RR-NSVT (+) groups (log-rank p=0.815).
Figure 4
A Kaplan-Meier curve of VTA occurrence between patients without RR-NSVT (RR-NSVT [-]) and those with RR-NSVT with (RR-NSVT [+] and cluster NSVT [+]) or without a cluster NSVT (RR-NSVT [+] and cluster NSVT [-]). Event-free survival was significantly different among the three groups (p<0.001). Event-free survival was lower in RR-NSVT (-) compared to both RR-NSVT (+) and cluster NSVT (-) (p<0.001), and RR-NSVT (+) and cluster NSVT (+) (p<0.001). The log-rank p value was 0.050 between RR-NSVT (+) and cluster NSVT (-) and between RR-NSVT (+) and cluster NSVT (+).